Studying SARS-CoV-2 in European patients




LEOSS is generously supported by


The new SARS CoV II 2019 is spreading rapidly. Mandated by the ESCMID Emerging Infections Task Force (EITaF) and supported by the German Infectious Disease Society we want to better understand the implications of the new virus on patients by systematically documenting patient data across Europe.

373 🧑
People
Involved

44 🏥
Confirmed
Sites

169 📝
Cases
Documented

Status Report

LEOSS Sites

Updated: 27.03.2020


Logo LEOSS fighting SARS-CoV-2website small
  • 10 -25min documentation / patient
  • no informed consent necessary (anonymous reports)
  • all hospitalized patients including children eligible
  • retrospective documentation after discharge / death
  • immediate start after positive ethic vote

Why:

The SARS-CoV-2 pandemic is a major challenge for medical professionals worldwide, with a daily increase of new infections. Currently, there is a gap of knowledge regarding best possible clinical management of the infection as well as prediction and prevention of severe outcomes.

How:

Studying SARS-CoV-2  in European patients
Protocol

We initiated the Lean European Open Survey on SARS-CoV-2 (LEOSS) project, a prospective European multi-center cohort study, to get more in-depth knowledge about the epidemiology and clinical course of patients infected with SARS-CoV-2. Our goal is to establish a quick and simple register that allows anonymous documentation of patients. This data can be used to identify independent predictors of outcome in patients with diagnosed infection by SARS-CoV-2. The study will allow retrospective inclusion of patients treated before initiation of the study.

Study Population:

blank europe map

Patients who were diagnosed or received treatment in one of the member states of the EU/EEA for SARS-CoV-2 (PCR confirmed).

Variables:

Studying SARS-CoV-2  in European patients
Data Items

The eCRF will ensure the documentation of the following items:

  • Age category, gender, ethnicity
  • Country of origin, country of diagnosis, ethnicity
  • Assumed time of contracting infection
  • Important comorbidities
  • Observed stages of disease (uncomplicated phase, complicated phase, critical phase, recovery phase), each with time to event
  • Baseline values
  • and more…